Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Lymphoma 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Large B-Cell, Diffuse 21Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hodgkin Disease 15Lymphoma, T-Cell, Cutaneous 13Leukemia, Lymphocytic, Chronic, B-Cell 12Mycosis Fungoides 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Acute 11Burkitt Lymphoma 11Sezary Syndrome 9Lymphoma, Large-Cell, Anaplastic 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, T-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Immunoblastic Lymphadenopathy 7Blast Crisis 7Myeloproliferative Disorders 6Lymphoma, Extranodal NK-T-Cell 6Lymphoma, B-Cell 6Leukemia 6Waldenstrom Macroglobulinemia 5Recurrence 5Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Myeloid, Accelerated Phase 5Congenital Abnormalities 5

Interventions

dacetuzumab 2ficlatuzumab 1Vorinostat 1Tinzaparin 1Lenalidomide 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vascular Diseases × Vorinostat × Lymphoid × Clear all
NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Merck Sharp & Dohme LLC

Phase 3 Completed
637 enrolled 15 charts
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡